 |
9 Diseases |  |
0 Trials |
|
0 Trials |  |
22 News |  |
- | H7N9 Anhui 2013/AA ca / National Institute of Allergy and Infectious Diseases
Trial completion: A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine (clinicaltrials.gov) - Feb 11, 2019
P1, N=62, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed
- | H7N9 Anhui 2013/AA ca / National Institute of Allergy and Infectious Diseases
Trial completion date, Trial primary completion date: A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine (clinicaltrials.gov) - Oct 29, 2018
P1, N=62, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Trial completion date: Jun 2018 --> Oct 2018 | Trial primary completion date: Jun 2018 --> Oct 2018
- | H7N9 Anhui 2013/AA ca / National Institute of Allergy and Infectious Diseases
Trial completion: Safety and Immunogenicity of Priming With Live Attenuated A/H7N9 Influenza Virus Vaccine Followed By Inactivated A/H7N9 Influenza Virus Vaccine With AS03 Adjuvant (clinicaltrials.gov) - Sep 4, 2018
P1, N=72, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial completion date: Jun 2018 --> Oct 2018 | Trial primary completion date: Jun 2018 --> Oct 2018 Active, not recruiting --> Completed
- | H7N9 Anhui 2013/AA ca / National Institute of Allergy and Infectious Diseases
Enrollment closed, Enrollment change: A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine (clinicaltrials.gov) - Feb 19, 2018
P1, N=62, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=100 --> 62
- | H7N9 Anhui 2013/AA ca / National Institute of Allergy and Infectious Diseases
Enrollment closed, Trial primary completion date: Safety and Immunogenicity of Priming With Live Attenuated A/H7N9 Influenza Virus Vaccine Followed By Inactivated A/H7N9 Influenza Virus Vaccine With AS03 Adjuvant (clinicaltrials.gov) - Feb 12, 2018
P1, N=72, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting | N=100 --> 62 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2017 --> Jun 2018
- | H7N9 Anhui 2013/AA ca / National Institute of Allergy and Infectious Diseases
Enrollment open: Safety and Immunogenicity of Priming With Live Attenuated A/H7N9 Influenza Virus Vaccine Followed By Inactivated A/H7N9 Influenza Virus Vaccine With AS03 Adjuvant (clinicaltrials.gov) - May 10, 2017
P1, N=72, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2017 --> Jun 2018 Not yet recruiting --> Recruiting
- | H7N9 Anhui 2013/AA ca / National Institute of Allergy and Infectious Diseases
Trial primary completion date: A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine (clinicaltrials.gov) - Feb 20, 2017
P1, N=100, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Recruiting Trial primary completion date: Nov 2016 --> Jun 2018
- H7N9 Anhui 2013/AA ca / National Institute of Allergy and Infectious Diseases
Trial completion: Evaluating the Safety and Immunogenicity of a H7N9 Vaccine for the Prevention of Influenza H7N9 Disease in Adults 50 to 70 Years Old (clinicaltrials.gov) - Feb 1, 2017
P1, N=24, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Nov 2016 --> Jun 2018 Active, not recruiting --> Completed
- H7N9 Anhui 2013/AA ca / National Institute of Allergy and Infectious Diseases
New P1 trial: Safety and Immunogenicity of Priming With Live Attenuated A/H7N9 Influenza Virus Vaccine Followed By Inactivated A/H7N9 Influenza Virus Vaccine With AS03 Adjuvant (clinicaltrials.gov) - Nov 8, 2016
P1, N=72, Not yet recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- H7N9 Anhui 2013/AA ca / National Institute of Allergy and Infectious Diseases
Trial completion: Safety and Immunogenicity of a Live Attenuated H7N9 Influenza Virus Vaccine in Healthy Adults (clinicaltrials.gov) - Jul 28, 2016
P1, N=48, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- H7N9 Anhui 2013/AA ca / National Institute of Allergy and Infectious Diseases
Trial primary completion date: A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine (clinicaltrials.gov) - Jul 19, 2016
P1, N=100, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Trial primary completion date: Aug 2015 --> Nov 2016
- H7N9 Anhui 2013/AA ca / National Institute of Allergy and Infectious Diseases
Trial primary completion date: Safety and Immunogenicity of a Live Attenuated H7N9 Influenza Virus Vaccine in Healthy Adults (clinicaltrials.gov) - Mar 18, 2016
P1, N=48, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Aug 2015 --> Nov 2016 Trial primary completion date: Mar 2014 --> Mar 2016
- H7N9 Anhui 2013/AA ca / National Institute of Allergy and Infectious Diseases
Enrollment closed, Trial primary completion date: Evaluating the Safety and Immunogenicity of a H7N9 Vaccine for the Prevention of Influenza H7N9 Disease in Adults 50 to 70 Years Old (clinicaltrials.gov) - Mar 18, 2016
P1, N=24, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Mar 2014 --> Mar 2016 Recruiting --> Active, not recruiting | Trial primary completion date: May 2015 --> May 2016
- H7N9 Anhui 2013/AA ca / National Institute of Allergy and Infectious Diseases
Enrollment open: A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine (clinicaltrials.gov) - Aug 17, 2015
P1, N=100, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting | Trial primary completion date: May 2015 --> May 2016 Not yet recruiting --> Recruiting
- H7N9 Anhui 2013/AA ca / National Institute of Allergy and Infectious Diseases
Trial completion: Evaluating the Safety and Immune Response to a Live H7N9 Influenza Virus Vaccine Followed by an Inactivated H7N9 Influenza Virus Vaccine, Given at Varying Intervals (clinicaltrials.gov) - Mar 31, 2015
P1, N=100, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Recruiting Recruiting --> Completed
- H7N9 Anhui 2013/AA ca / National Institute of Allergy and Infectious Diseases
Enrollment open: Evaluating the Safety and Immunogenicity of a H7N9 Vaccine for the Prevention of Influenza H7N9 Disease in Adults 50 to 70 Years Old (clinicaltrials.gov) - Dec 19, 2014
P1, N=24, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed Not yet recruiting --> Recruiting
- H7N9 Anhui 2013/AA ca / National Institute of Allergy and Infectious Diseases
New P1 trial: Evaluating the Safety and Immunogenicity of a H7N9 Vaccine for the Prevention of Influenza H7N9 Disease in Adults 50 to 70 Years Old (clinicaltrials.gov) - Oct 24, 2014
P1, N=24, Not yet recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- H7N9 Anhui 2013/AA ca / National Institute of Allergy and Infectious Diseases
New P1 trial: A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine (clinicaltrials.gov) - Sep 29, 2014
P1, N=100, Not yet recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- H7N9 Anhui 2013/AA ca / National Institute of Allergy and Infectious Diseases
New P1 trial: Evaluating the Safety and Immune Response to a Live H7N9 Influenza Virus Vaccine Followed by an Inactivated H7N9 Influenza Virus Vaccine, Given at Varying Intervals (clinicaltrials.gov) - May 27, 2014
P1, N=100, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- H7N9 Anhui 2013/AA ca / National Institute of Allergy and Infectious Diseases
Enrollment open: Evaluating the Safety and Immune Response to a Live H7N9 Influenza Virus Vaccine Followed by an Inactivated H7N9 Influenza Virus Vaccine, Given at Varying Intervals (clinicaltrials.gov) - May 27, 2014
P1, N=100, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- H7N9 Anhui 2013/AA ca / National Institute of Allergy and Infectious Diseases
Enrollment closed: Safety and Immunogenicity of a Live Attenuated H7N9 Influenza Virus Vaccine in Healthy Adults (clinicaltrials.gov) - Jan 14, 2014
P1, N=48, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- H7N9 Anhui 2013/AA ca / National Institute of Allergy and Infectious Diseases
New P1 trial: Safety and Immunogenicity of a Live Attenuated H7N9 Influenza Virus Vaccine in Healthy Adults (clinicaltrials.gov) - Nov 24, 2013
P1, N=48, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)